Quarterly ResultMay 12, 2026, 04:14 PM
NeuroPace Q1 Revenue $22.1M; Raises 2026 Revenue Guidance to $99M-$101M
AI Summary
NeuroPace Inc. reported strong first-quarter 2026 financial results, with total revenue reaching $22.1 million and RNS System revenue growing 19.5% year-over-year. The company also raised its full-year 2026 revenue guidance to $99 million-$101 million and improved its Adjusted EBITDA loss outlook. Operational highlights include completing the FDA mid-cycle review for the NAUTILUS PMA supplement and achieving new highs in active prescribers and patient pipeline.
Key Highlights
- Q1 2026 total revenue was $22.1 million (GAAP) and $22.0 million (non-GAAP, excluding DIXI Medical), up 20.1% YoY (non-GAAP).
- RNS System revenue grew 19.5% YoY to $21.7 million in Q1 2026.
- GAAP net loss for Q1 2026 was ($6.7) million, compared to ($6.6) million in Q1 2025.
- Adjusted EBITDA loss (excluding DIXI Medical) improved to ($3.3) million in Q1 2026 from ($4.1) million in Q1 2025.
- Full-year 2026 revenue guidance raised to $99 million-$101 million, up from $98 million-$100 million.
- Full-year 2026 Adjusted EBITDA guidance improved to ($8.5) million-($9.5) million from ($9.0) million-($10.0) million.
- Completed FDA mid-cycle review for NAUTILUS PMA supplement, expecting IGE indication approval mid-2026.
- Cash, cash equivalents, short-term investments, and restricted cash totaled $54.8 million as of March 31, 2026.